Standard usage, dosage and medication precautions of acalatinib

Acalabrutinib (also known as acalabrutinib, English name: Acalabrutinib) is a selective BTK (Brutontyrosine kinase) inhibitor, which belongs to the second generation BTK pan>Targeted drugs are widely used to treat a variety of B cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Its target is more precise and has fewer side effects. It is one of the BTK drugs that has attracted much attention in recent years. In clinical application, the correct usage and dosage of acotinib and the precautions for taking the drug are crucial to exert the therapeutic effect and reduce adverse reactions.

1. Standard usage and dosage of acotinib

The recommended dose of acotinib varies slightly depending on the indications, but generally follows the basic regimen of "orally administered twice daily".

Standard dose for adults:100mg, twice daily (once every 12 hours), continuously without interruption.

Dosage form specifications: The current common specifications are 100mg tablets. The way to take the medicine is to swallow the whole tablet and do not crush, chew or break it.

Medication cycle: acotinib is continued to be administered until disease progression or intolerable adverse reactions occur. In clinical practice, there is generally no fixed course of treatment, but whether to continue treatment depends on the efficacy and patient tolerance.

No dose adjustment is usually required in patients with renal or mild to moderate hepatic impairment. However, for patients with severe liver function impairment, there is no sufficient data to support it, so it needs to be used with caution and it is recommended to follow the doctor's advice.

2. The relationship between medication time and diet

Acotinib can be taken on an empty stomach or with food; food does not significantly affect the absorption of the drug. However, in order to improve patient compliance and reduce gastrointestinal irritation, many doctors recommend that patients take it with food. At the same time, care should be taken to avoid taking it at the same time with acidic drugs (such as anti-gastric drugs), because the dissolution and absorption of acotinib requires the participation of gastric acid.

Proton pump inhibitors (such as omeprazole): Try to avoid coadministration with acotinib;

H2Receptor antagonists (such as ranitidine): The interval between taking acotinib and acotinib should be at least 2 hours;

Antacids (such as calcium carbonate): It is recommended to use them 2 hours before taking the medicine or 2 hours after taking the medicine.

These gastric drugs will neutralize gastric acid and affect the solubility and absorption efficiency of acotinib, which may affect the efficacy of the drug.

3. Interactions with other drugs

Acotinib is metabolized by the CYP3A enzyme and therefore interacts with drugs that affect CYP3A activity:

StrongCYP3A Inhibitors (such as ketoconazole, clarithromycin): can significantly increase the plasma concentration of acotinib and increase the risk of toxicity, so use caution or reduce the dose of acotinib;

StrongCYP3A inducers (such as rifampicin, carbamazepine): may reduce the efficacy of acotinib, avoid simultaneous use;

Anticoagulant drugs: When using anticoagulant drugs such as warfarin and rivaroxaban, the risk of bleeding needs to be monitored.

Therefore, patients should inform their doctors about all medications they are taking, including over-the-counter drugs and health supplements, while taking acotinib.

4. Medication Precautions and Side Effect Management

1. Risk of bleeding

BTKOne of the common side effects of inhibitor drugs is bleeding tendency. Some patients may experience nosebleeds, bleeding gums, or even severe internal bleeding.

Advise patients to avoid engaging in strenuous exercise or using equipment that may cause trauma;

Medication should be stopped before surgery or dental procedures or the timing of medication discontinuation should be communicated with the doctor;

People taking concomitant anticoagulants or antiplatelet drugs should be particularly aware of the risks.

2. Infection risk

Acotinib may slightly suppress the immune system and increase the risk of viral, bacterial, and fungal infections.

It is recommended that patients avoid contact with people with infectious diseases such as influenza and herpes zoster during treatment;

Consider preventive anti-infective treatment when necessary. For example, hepatitis B carriers should be monitored for viral activation;

If you develop fever, cough, sore throat and other symptoms, you should seek medical advice promptly.

3. Abnormal heart rhythm

A very small number of patients may develop arrhythmias such as atrial fibrillation while taking acotinib.

For those with a history of heart disease, electrocardiogram monitoring should be strengthened in the early stages of medication;

If symptoms such as chest tightness and irregular heartbeat occur, you need to seek medical treatment as soon as possible and consider adjusting the treatment plan.

4. Headache and fatigue

Some patients may experience mild headache or fatigue in the early stages of taking it, which is usually a reversible reaction.

It generally does not affect continued treatment, and acetaminophen can be considered to relieve headaches;

Fatigue may gradually lessen as the body adapts to the medication rhythm.

5. Precautions when discontinuing and changing medications

If acotinib needs to be discontinued due to adverse reactions or disease progression, the drug should not be stopped suddenly, but should be gradually transitioned to other drugs according to the doctor's instructions to avoid tumor rebound or other complications. For some patients who develop drug resistance, doctors may recommend switching to third-generation BTK inhibitors (such as zanubrutinib) or combination immunotherapy and chemotherapy.

As a second-generation BTK inhibitor, acotinib has clear efficacy in the treatment of chronic lymphocytic leukemia and other B cell malignancies. It has higher selectivity and more controllable side effects. It is one of the important drugs widely used in clinical practice. During use, patients should strictly follow the recommended dosage rules and pay attention to drug interactions and possible side effects. At the same time, maintaining communication with the doctor and reviewing on time are the keys to ensuring treatment effectiveness and medication safety. Scientific use of acotinib will help patients achieve more durable and safer disease control.

Reference materials:https://www.drugs.com